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INTRODUCTION
Ménière’s disease is a clinical syndrome of recurrent episodes of vertigo, low- to mid-frequency sensorineural hearing loss, and fluc-
tuating aural fullness, tinnitus, and hearing levels that are associated with vertigo episodes[1,2]. The reported prevalence has varied 
widely across studies ranging from 3.5 to 513 per 100.000 individuals [3-5]. Affected individuals suffer impaired overall quality of life 
[6] and disease-specific quality of life [7, 8].
The pathophysiology of Ménière’s disease is unknown, although dilation of the membranous labyrinth (i.e., endolymphatic hydrops) 
is a closely associated finding on post-mortem studies [9] and, increasingly, on in vivo imaging as well [10, 11]. Owing to the unclear 
pathophysiology of Ménière’s disease, the optimal treatment is also unknown [12]. However, many treatment options are offered by 
clinicians; some of which include dietary modifications, medical management with diuretics, steroids or betahistine, and surgeries, 
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such as decompression of the endolymphatic sac [13]. Famously, in a 
vast review of literature, Torok reported in 1977 that the authors con-
sistently identify improvements in 60%-80% of patients regardless 
of the intervention used [14]. Few studies have observed the natural 
history of the disease [15], but among placebo-controlled studies, the 
authors have reported over a 50% reduction in attack frequency at 9 
months [16] and improvements in Ménière’s disease symptoms more 
broadly at 1 year [17]. In some patients with medically refractory re-
current vertigo, ablative therapies that destroy labyrinthine function, 
such as intratympanic gentamicin, vestibular neurectomy, and sur-
gical labyrinthectomy, are effective at reducing episodes of vertigo, 
but with either sacrifice or risk to residual hearing and any remaining 
vestibular function in the treated ear.
With many treatment options available and without consensus on 
optimal care, patients with Ménière’s disease are likely to be offered 
therapy dependent on the preferences of providers at the clinics to 
which they present. We had hypothesized that a national survey of 
patients with Ménière’s disease would identify which of the many 
available treatments patients report as being more or less effective. 
The aim of the present study was to assess the cross-sectional preva-
lence of different treatment approaches to Ménière’s disease, as well 
as the patient-reported effectiveness of their most recent interven-
tion in a nationally representative sample of Italian patients.
MATERIALS AND METHODS
Participants completed an online Italian language questionnaire 
(www.surveymonkey.com) about the treatment of their Ménière’s 
disease and its impact on their quality of life. Recruitment occurred 
over 6 months between July 2015 and January 2016. The question-
naire was distributed by two Italian non-profit support organizations 
for patients with Ménière’s disease (Associazione Malati Ménière In-
sieme and Associazione Italiana Malati di Ménière ONLUS). Inclusion 
criteria for the study were: (a) diagnosis of definite Ménière’s disease 
according to either the American Academy of Otolaryngology-Head 
and Neck Surgery guidelines or the 2015 Barany Society guidelines 
as determined by the patient’s otolaryngologist and (b) disease dura-
tion of at least 6 months. Prior to joining the organizations, prospec-
tive members undergo an interview to confirm a clinician diagnosis 
of Ménière’s disease. A link to the survey was electronically distribut-
ed by the organizations to members. Approximately 400 members 
received the link to a questionnaire. Anonymous data were stored 
electronically by the hosting survey website and downloaded for 
analysis at the completion of recruitment.
An English language translation of the complete questionnaire is in-
cluded in Appendix A. The questionnaire was translated and agreed 
upon by bilingual members of the research team.
The questionnaire consisted of 17 items. Demographic data includ-
ing age, gender, and date of initial diagnosis were collected in Ques-
tions 1-3. Question 4 asked respondents to report the most recent 
treatments received for their Ménière’s disease. Major therapeutic 
categories included “betahistine,” “diuretics,” “oral steroids,” “dietary 
modifications,” “cinnarizine,” “tympanostomy tube,” “surgery of the 
nerve or inner ear,” “intratympanic gentamicin,” or “others.” Selecting 
“others” prompted respondents to specify the treatment provided. 
Multiple selections were permitted. Questions 5 and 6 requested 
the estimated number of vertigo episodes per month prior to and 
following the most recent treatment. Items from the Social Life and 
Work Impact of Dizziness (SWID)-4 Questionnaire were included in 
the subsequent questions [18]. The SWID-4 short form questionnaire 
is a series of four questions that assess the effects of dizziness on so-
cial life, family life, work, and abilities to travel. This instrument was 
chosen due to its simplicity and the authors’ prior use of these items 
in a validation study of the SWID-4[18]. Available responses are bina-
ry (yes/no). Participants were asked to provide responses indicating 
their limitations prior to and following their most recent therapies 
for Ménière’s disease. For questions about work limitations, respon-
dents could also indicate “unemployed or retired.” If participants did 
not select “unemployed or retired,” they were then asked to estimate 
the number of days off work per month attributable to Ménière’s 
disease before and after their most recent treatment. The final ques-
tion requested respondents to evaluate, based on their experience, 
which treatment they would recommend to a patient suffering from 
Ménière’s disease.
A total SWID-4 score was calculated for each respondent by defining 
“yes” responses as 1 and “no” responses as 0 and summing the re-
sponses. Higher values indicate greater functional limitations. 
Statistical Analysis
Statistical analysis was conducted by paired Student’s t-test for pre- 
and post-treatment responses of continuous variables, and Fish-
er’s exact test for binary variables. Between-group comparisons of 
continuous variables were performed using ANOVA with post-hoc 
pairwise comparisons performed if statistically significant. A p<0.05 
was considered statistically significant. All data were analyzed using 
GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). Ethical 
approval was obtained from the ethics committee of University of 
Siena. Informed consent was included as part of the online survey.
RESULTS
A total of 176 respondents participated in the study. Six respondents 
submitted incomplete questionnaires, and their data were excluded 
in the analysis. Demographic and clinical data are shown in Table 1. 
There were no significant differences between men and women in 
mean number of vertigo episodes per month, mean days off work 
due to Ménière’s disease per month, or SWID-4 scores (p>0.05). Re-
spondents most commonly indicated that their last treatments in-
cluded: dietary modifications, followed by diuretics, betahistine, oral 
steroids, and intratympanic gentamicin. They selected “others” as fre-
quently as betahistine (41%). When specifying further, respondents 
selecting “others” reported having received any of 19 additional dif-
ferent therapies for their Ménière’s disease. These included medical 
therapies, such as cinnarizine or cinnarizine/dimenhydrinate, citico-
line, thiethylperazine, delorazepam or clonazepam, sulodexide, ni-
modipine, lipoflavonoid cereals, and levosulpiride, as well as hospital 
admission for intravenous mannitol or glycerol. Procedures described 
under “others” included intratympanic steroids, tympanostomy tube 
placement, acupuncture, “surgery of the nerve or inner ear,” endo-
lymphatic sac decompression and shunt, and percutaneous translu-
minal angioplasty for chronic cerebrospinal venous insufficiency.
A large proportion (121/170, 71%) of respondents reported having 
received at least two treatments simultaneously. Betahistine (58/69, 
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84%), diuretics (77/80, 96%), steroids (47/48, 98%), and dietary modi-
fications (81/93, 87%) were the most common treatments prescribed 
in combination, whereas intratympanic gentamicin was uncommon-
ly provided as part of combination therapy (6/19, 32%).
Among all respondents, both the mean number of days per month 
off work due to Ménière’s disease and the mean count of vertigo 
episodes per month significantly improved after their most recent 
treatment (p<0.0001; Table 1). When separating the study popula-
tion by treatment type-understanding the high rate of combination 
therapy–each group had a similar mean number of vertigo episodes 
per month before treatment (p>0.05); however, each of the most fre-
quently reported therapeutic options was effective in reducing ver-
tigo episode count (p<0.005, t-test; Figure 1). Of the treatments, in-
tratympanic gentamicin had the greatest absolute reduction (8.3±7.3 
vs. 1.5±1.9 episodes, p=0.0004, t-test). Owing to the small sample of 
respondents indicating having received one of the many treatments 
in the category “others,” these treatments were not analyzed sepa-
rately. However, given the reported effectiveness of all the most 
commonly used treatments at reducing vertigo episode count, we 
hypothesized that combining the other treatments into a single cat-
egory would also demonstrate effectiveness. Respondents who se-
lected “others” also reported significantly fewer vertigo episodes per 
month (4.7±6.7 vs. 1.8±3.4, p=0.0026). After treatment, each group 
had a similar mean number of vertigo episodes per month (p>0.05).
Similarly, before treatment, each group had a similar mean number 
of days off work per month due to Ménière’s disease (p>0.05). Follow-
ing treatment, there was a reduction in days per month off work due 
to Ménière’s disease for each of the most frequently reported thera-
peutic options (p<0.05, t-test; Figure 2), except for the oral steroids 
group (p=0.122, t-test). There were also no differences across the 
treatment groups in the mean number of days off work per month 
due to Ménière’s disease after treatment (p>0.05).
The four SWID questions assessing lifestyle limitations were also 
compared before and after treatment among all respondents and 
separated by the treatment groups. Among all respondents, the 
Table 1. Demographic and clinical data of all respondents
N=170 respondents   Statistic
Age, years  50.3±12.3 –
Male/female ratio  41/129 –
Duration of MD, years  7.8±7.9 –
Mean number of vertigo episodes per month  
(before last treatment)  5.7±7.6 p<0.0001
Mean number of vertigo episodes per month  
(after last treatment)  2.6±4.6 
No. of subjects retired/unemployed (%) 32 (19%) –
Days off work due to MD per month  
(before last treatment)*  10.1±9.2 p<0.0001
Days off work due to MD per month  
(after last treatment)*  4.2±6.7 
SWID-4 total score before treatment 3.3±1.0 p<0.0001
SWID-4 total score after treatment 1.9±1.5 
No. of treatments (%) 1 49 (29%) –
 2 64 (38%) 
 3 29 (17%) 
 >3 28 (16%) 
No. of subjects in each  
treatment group (%) # Diuretics 80 (47%) –
 Betahistine 69 (41%) 
 Oral steroids 48 (28%) 
 Dietary 93 (55%) 
 IT gentamicin 19 (11%) 
 Others 69 (41%) 
MD: Ménière’s disease; IT: intratympanic; SWID: Social Life and Work Impact of Dizziness
*This value does not include respondents who indicated “retired/unemployed.”
#Percentages do not add to 100% as many respondents received at least two treat-
ments simultaneously.
Figure 2. Mean (SD) number of days off work per month due to Ménière’s disease 
before and after treatment, by treatment group.
Figure 1. Mean (SD) episodes of vertigo per month before and after treatment, 
by treatment group.
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SWID-4 total score significantly decreased after the most recent 
treatment (p<0.0001; Table 1). For each of the SWID-4 questions, af-
ter treatment, respondents reported fewer limitations in working life 
(84% vs. 69%, p=0.0108, Fisher’s exact test), social activities (89% vs. 
53%, p<0.0001, Fisher’s exact test), family life (79% vs. 43%, p<0.0001, 
Fisher’s exact test), and ability to travel (78% vs. 44%, p<0.0001, Fish-
er’s exact test; Figure 3). Most respondents experienced working 
limitations before treatment and reported a significant improve-
ment after any of the therapeutic options (Figure 4). An even greater 
treatment effect was observed for limitations in social life (Figure 4), 
family life, and ability to travel (Figure 5). However, among the treat-
ment groups, those respondents receiving intratympanic gentamicin 
reported the greatest absolute reductions in limitations at work (64% 
vs. 21%), social life (94% vs. 37%), family life (89% vs. 16%), and ability 
to travel (89 vs. 26%, p<0.05 for each, Fisher’s exact test). In addition, 
those receiving intratympanic gentamicin had the lowest proportion 
of respondents reporting limitations after treatment for each of the 
SWID questions.
The final question asked which treatment the respondent would rec-
ommend to a patient diagnosed with Ménière’s disease. The most 
recommended treatments were dietary modifications (45%), diuret-
ics (31%), betahistine (29%), gentamicin (16%), and steroids (14%). 
One-quarter (25%) of respondents were unable to suggest any treat-
ment based on their experience. When comparing these results to 
the percentages of most recent treatments received by respondents, 
only gentamicin showed a favorable recommendation (+5%), where-
as all other treatment options demonstrated a decrease in willing-
ness to recommend a received treatment, ranging from -24% (dietary 
modifications) to -12% (betahistine).
DISCUSSION
The present study identified a broad range of treatments used in a 
large nationally representative Italian population of patients with 
Ménière’s disease. The most frequently reported treatments included 
conservative therapies, such as dietary modifications, or the medi-
cations betahistine and oral diuretics. Other common treatments in-
cluded oral steroids and vestibular suppressants, such as benzodiaz-
epines or the antihistamine and calcium-channel blocker cinnarizine. 
These therapies were often used in combination.
Approximately 12% of patients reported that their last treatment 
was destructive therapy, such as chemical labyrinthectomy with in-
tratympanic gentamicin or vestibular neurectomy. Many other treat-
ments with varying side effect profiles were also listed by patients 
ranging from the relatively benign, such as lipoflavonoid cereals and 
acupuncture, to the more invasive, including tympanostomy tubes, 
hospital admission for intravenous glycerol or mannitol, endolym-
phatic shunt placement, and endovascular dilations of the cervical 
venous drainage, a procedure reported as being used by 10 patients 
in the present study. Overall, 24 different treatments were reported 
by patients as therapy for their Ménière’s disease.
Similarly, in other studies, patients reported significant disability as-
sociated with their disease, with the majority indicating limitations 
at work, social or family life, and traveling. Nineteen percent reported 
being unemployed, with several adding comments that they lost their 
job as a result of Ménière’s disease. Ménière’s disease is known to be 
Figure 3. Proportion of all respondents reporting limitations in each SWID-4 
question before and after treatment.
Figure 4. Proportion of respondents reporting limitations in working life and so-
cial activities before and after treatment, by treatment group. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.
Figure 5. Proportion of respondents reporting limitations in family life and trav-
eling ability before and after treatment, by treatment group. ns, not significant, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.***p<0.001, ****p<0.0001.
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impairing to the overall health-related quality of life, with one study 
showing over 40% reduction compared with a healthy adult popu-
lation [6]. Patients often report vertigo as the most debilitating symp-
tom[19], and the accompanying anxiety related to the unpredictable 
nature of attacks leads to limitations in social activities and work [20,21]. 
Fortunately, vertigo is also the symptom most likely to improve fol-
lowing treatment [22], and vertigo episode counts have been the most 
commonly used outcome measure in studies of Ménière’s disease.
Perhaps unsurprising given the history of treatments for Ménière’s 
disease, all of the many treatments in the present study were re-
ported by patients as effective, with respondents reporting fewer 
episodes of vertigo, regardless of treatment type, as well as reduced 
numbers of absentee days from work. This observation occurred 
despite the treatments targeting several different proposed disease 
mechanisms (e.g., hydrops, inflammatory, allergic, vascular, and 
channelopathy). However, this is consistent with the report by Torok, 
who noted a treatment effect in Ménière’s disease regardless of the 
chosen management approach [14].
This finding supports a strong placebo effect in the treatment of 
Ménière’s disease and also highlights one of the challenging aspects 
of studying this condition: it is a disabling condition, but spontaneous 
remissions are common. As a result of the unclear pathophysiology, 
a myriad of treatments has been proposed, the majority of which has 
not been subject to randomized placebo-controlled studies of ade-
quate duration. Sam Crowe, former chairman of Otolaryngology—
Head and Neck Surgery at Johns Hopkins Hospital, described in 1938 
the available treatments for Ménière’s disease, prior to Walter Dan-
dy’s popularizing of the vestibular nerve section: “the attacks were 
extremely severe and disabling, so much so that, having already tried 
one or more of the commonly employed therapeutic measures, such 
as dietary treatment and drugs, removal of teeth, tonsils, appendix or 
gall bladder, and in some cases extensive nasal sinus or pelvic oper-
ations, [patients] came to the hospital to have their vestibular nerve 
divided” [23]. Since 1861 when Prosper Ménière localized recurrent ep-
isodes of vertigo to the inner ear, physicians have been seeking novel 
approaches to relieve suffering from his eponymous syndrome.
Fortunately for patients, recovery is common regardless of the ther-
apeutic approach. However, physicians should consider carefully the 
risk of each proposed therapy and counsel patients about the likeli-
hood of recovery with various treatments.
However, as also described in Torok’s report, not all patients recover. 
In the present study, although after treatment a smaller proportion of 
respondents indicated limitations in the quality of life, over 40% con-
tinued to report impairments at work, in social or family activities, and 
in travel capabilities. This also contributes to why the majority of pa-
tients were treated with multiple therapies. While it may be presumed 
that at least some of the therapies are not addressing the true under-
lying pathophysiology of Ménière’s disease, it is unknown whether this 
ongoing disability is due to recurrent episodes, hearing loss, unilateral 
vestibular impairment, or persistent postural–perceptual dizziness. 
Other studies, for example, have shown impaired health-related quali-
ty of life in some patients with Ménière’s disease many years even after 
ablative treatment [24]. We included a limited number of demographic 
variables in our survey. Hearing loss or tinnitus, for instance, were not 
assessed and may differ among the treatment groups or could be ac-
counting for long-term impairments in the quality of life. The reasons 
for these lasting effects on the quality of life in patients with treated 
Ménière’s disease deserve additional study.
This was a retrospective study so causation cannot be determined. 
However, it was noteworthy that of the treatments identified by the 
survey, intratympanic gentamicin showed the greatest treatment 
effect, as represented by larger reductions in both self-reported ver-
tigo episodes and work absenteeism. Patients who received genta-
micin also had greater reductions in the proportion that indicated 
limitations in work, social activities, family activities, or travel com-
pared with other treatments. Although one might expect similar 
beneficial effects after surgical labyrinthectomy or vestibular neu-
rectomy, there were too few patients reporting these treatments in 
the present study to allow a separate analysis. Longitudinal studies 
have also shown improved quality of life measures after both surgical 
and chemical labyrinthectomy [25, 26]. However, patients receiving de-
structive therapies in the present study had more frequent episodes 
of vertigo prior to the intervention, likely prompting their providers 
to offer more aggressive treatment. This higher pre-treatment value 
contributed to the greater treatment effect observed for gentamicin 
compared with the other treatments. However, in addition to this 
greater reduction in vertigo episodes and work absenteeism, the 
proportion of patients reporting limitations in the quality of life was 
substantially smaller than post-treatment values for other therapies. 
These findings suggest greater effectiveness of intratympanic gen-
tamicin for reducing vertigo episodes and improving the quality of 
life in Ménière’s disease. Furthermore, respondents were likely to rec-
ommend this treatment for another patient with Ménière’s disease.
In the present study, the outcome measure “lost days of work per 
month due to disease” showed a greater treatment effect compared 
with episodes of vertigo, suggesting that this measure might be use-
ful for future studies. While other cross-sectional studies have noted 
substantial impairment in work-related productivity in patients with 
vestibular disease [18, 24], to our knowledge, none has used this as an 
outcome measure for a treatment effect. Work-related absenteeism–
while a secondary effect of disease symptoms–may better reflect 
functional impairment due to disease than vertigo episode counts. 
However, a clear limitation of this outcome is that when questioned 
about work absenteeism, approximately 19% of participants report-
ed retirement from work or current unemployment and were exclud-
ed from this part of the analysis.
Response biases may have contributed to a greater likelihood of 
participants attributing an improvement in functional limitations to 
recent treatment. However, it is worth noting that the mean num-
bers of vertigo episodes reported per month in the present study 
before (5.7, standard deviation (SD) 7.6) and after (2.6, SD 4.6) the 
most recent treatments were comparable to a recent well-designed 
placebo-controlled study [16]. Adrion et al. [16] reported that at study 
enrollment, participants in the placebo group experience 6.2 (SD 6.9) 
mean vertigo episodes per month that decreased to 2.7 (95% confi-
dence interval 1.3-6.3) episodes per month over 7-9 months of pla-
cebo treatment. It appears that patients with Ménière’s disease start 
new medications or enroll in clinical trials when their symptoms are 
most severe and then improve over the subsequent months, regard-
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less of treatment approach. All participants in the present study were 
recruited from two national organizations for patients with Ménière’s 
disease and had been evaluated and treated by local physicians. 
While a diagnosis of definite Ménière’s disease was inclusion crite-
ria for the study, this could not be confirmed. However, the present 
study reflects current diagnostic and therapeutic patterns of Italian 
physicians seeing patients with recurrent vertigo and symptoms con-
sistent with Ménière’s disease. Furthermore, the majority of patients 
received multiple treatments, and close follow-up of each patient 
was not possible, impairing any assessment of treatment efficacy. 
Nevertheless, the study design provides a unique opportunity to as-
sess how patients receive and experience the effects of their thera-
pies in an unobserved setting.
CONCLUSION
This nationally representative cross-sectional survey of Italian pa-
tients with Ménière’s disease revealed a high prevalence of function-
al disability that persists in many patients despite treatment. How-
ever, regardless of the many treatment approaches, all therapies are 
associated with fewer reported mean vertigo episodes and fewer 
patients reporting impairments in the quality of life. Compared with 
other treatments, chemical labyrinthectomy with intratympanic gen-
tamicin was associated with the greatest treatment effect, providing 
the greatest reduction in both reported vertigo episodes and work-
place absenteeism, as well as the smallest proportion of patients 
reporting functional limitations after treatment. The findings in the 
present study support a prominent placebo effect in treatments for 
Ménière’s disease and highlight not only the challenges of studying 
outcomes in treatment for Ménière’s disease but also the critical need 
to better understand its pathophysiology.
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APPENDIX A: English language translation of the complete questionnaire.
Introduction for patients.
All the following questions concern any problems you may have in Postural Balance and/or Dizziness due to Meniere’s disease. The survey as-
sesses the impact of such symptoms on your working and social life before and after the last treatment you adopted. All replies are anonymous 
and in strict confidence. Thank you for your participation.
1) Please state your age in years.
2) Please state your gender (male/female).
3) Please specify the date when you were diagnosed with definite Meniere’s disease (exact date, year).
4) Which is the last treatment you used for Meniere’s disease? (Betahistine, diuretics, steroids, dietary changes, cinnarizine, tympanostomy 
tubes, surgery of the inner ear or vestibular nerve, intratympanic gentamicin injections, others [please specify]). Multiple answers are allowed.
5) How many vertigo episodes did you experience in the month before your most recent treatment for Meniere’s disease?
6) How many vertigo episodes did you experience in the month after the most recent treatment for Meniere’s disease?
7) Have balance/dizziness problems due to Meniere’s disease caused you difficulty at work before the most recent treatment was used? (YES 
NO/ UNEMPLOYED, RETIRED). IF YOU ARE NOT WORKING (UNEMPLOYED OR RETIRED), PLEASE GO TO QUESTION 11, Otherwise please continue 
with the next question.
8) Before the most recent treatment used for Meniere’s disease, how many average days per month did you take off work as a result of your 
disease.
9) Have balance/dizziness problems due to Meniere’s disease caused you difficulty at work after your most recent treatment? (YES/NO/ UN-
EMPLOYED, RETIRED).
10) After your most recent treatment for Meniere’s disease how many average days per month did you take off work as a result of your disease.
11) Have balance/dizziness problems due to Meniere’s disease caused difficulties in your social life before your most recent treatment (e.g. 
restrictions on going out, planning vacations, etc.)? (YES/NO)
12) Have balance/dizziness problems due to Meniere’s disease caused difficulties in your social life after your most recent treatment (e.g. r 
strictions on going out, planning vacations, etc.)? (YES/NO)
13) Have balance/dizziness problems due to Meniere’s disease caused difficulties in your family life before the most recent treatment used 
for Meniere’s disease? (YES/NO) 14) Have balance/ dizziness problems due to Meniere’s disease caused difficulties in your family life after your 
most recent treatment? (YES/NO)
15) Have balance/dizziness problems due to Meniere’s disease restricted your ability to travel (e.g. cannot ride a bicycle, travel by car, plane, 
etc.) before the most recent treatment used for Meniere’s disease? (YES/NO)
16) Have balance/dizziness problems due to Meniere’s disease restricted your ability to travel (e.g. cannot ride a bicycle, travel by car, plane, 
etc.) after your most recent treatment? (YES/NO)
17) Which treatment would you recommend to a patient suffering from Meniere’s disease (Betahistine, diuretics, steroids, dietary changes, 
cinnarizine, tympanostomy tubes, surgery of the inner ear or vestibular nerve, intratympanic gentamicin injections, others [please specify]). 
Multiple answers are allowed.
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